GuidelineEuropean radiology2025
Hypersensitivity reactions to contrast media: Part 2. Prevention of recurrent hypersensitivity reactions in adults. Updated guidelines by the ESUR Contrast Media Safety Committee.
Guideline in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety of positive gastrointestinal contrast media. Updated guidelines by the ESUR Contrast Media Safety Committee.European radiology · 2026Guideline
- Hypersensitivity reactions to contrast media: Part 1. Management of immediate and non-immediate hypersensitivity reactions in adults. Updated guidelines by the ESUR Contrast Media Safety Committee.European radiology · 2025Guideline
- [Contrast agent strategies in elective oncological imaging].Radiologie (Heidelberg, Germany) · 2026Review
- When the Flag Identifies the Territory But Not the Mechanism: Lessons From Contrast-Induced Kounis Syndrome.JACC. Case reports · 2026Article
- From knowing to acting: closing the emergency gap in contrast-induced anaphylaxis.European radiology · 2026Article
- Contrast Media Side Effects and Kounis Syndrome: Timeo Danaos et Dona Ferentes.Balkan medical journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity reactions to contrast media are infrequent and can occur either within the first 60 min following their intravascular administration (immediate reactions) or at a later time point (non-immediate reactions). Most hypersensitivity reactions are mild or moderate, while severe reactions are rare (less than 1 in every 10,000 administrations). After any moderate or severe immediate adverse reaction, serum tryptase must be measured within 1-4 h from the onset of symptoms and at least 24 h after symptoms have disappeared to confirm a hypersensitivity reaction. At least for all moderate-to-severe hypersensitivity reactions, the patient should be referred to a drug allergy specialist for an allergy evaluation with a panel of contrast media, and optionally, all hypersensitivity reactions when local drug allergy specialist capacity allows. Selecting an alternative contrast medium based on practical experience is challenging due to its high and variable cross-reactivity; therefore, the best option is to choose an alternative based on the results of an allergy evaluation. This approach is safer and more effective than premedication for preventing recurrent hypersensitivity reactions. KEY POINTS: Question What is the optimal strategy in clinical practice to prevent recurrent hypersensitivity reactions in adults who previously experienced a hypersensitivity reaction to contrast media? Findings Serum tryptase should be measured within 1-4 h after a moderate or severe reaction, and at least all moderate or severe hypersensitivity reactions should be referred to an allergologist. Clinical relevance Management strategies should be adapted to the type and severity of the reaction, as well as the urgency of required re-administration. Changing from the culprit contrast agent to another molecule with differing side-chains is more effective than premedication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.